IndustryCompany release

Emergent BioSolutions Q3 revenue falls 52% to $110.0M, with $32.7M net loss

🇺🇸 Emergent BioSolutions Inc. (EBS) · Mon 02 Nov 2026

The US biodefence and opioid-overdose company reported lower NARCAN, smallpox countermeasure and BAT sales, partly offset by higher CYFENDUS anthrax vaccine revenue.

Emergent BioSolutions reported third-quarter 2026 results on 2 November, with revenue of $110.0M against $231.1M in the same period a year earlier, a fall of 52%. The company recorded a net loss of $32.7M.

The company attributed the decline to lower sales of NARCAN, its smallpox medical countermeasures and BAT (botulism antitoxin heptavalent). Higher sales of CYFENDUS, its anthrax vaccine, offset part of the shortfall.

On the balance sheet, Emergent repurchased $75M of senior notes. It also carried out a restructuring, although the summary available does not give details of its scope or cost.

Emergent secured a contract modification for CYFENDUS worth roughly $24M, along with a standing offer for NARCAN in Canada. Separately, it announced that chief financial officer Rich Lindahl is to retire.

What it means for your team

  • Public-health procurement teams should note that Emergent's revenue remains heavily tied to government-linked countermeasure and overdose-reversal products, where quarterly sales can swing sharply.
  • The roughly $24M CYFENDUS contract modification points to continued demand for anthrax preparedness supplies.
  • The Canadian NARCAN standing offer is relevant for market-access teams tracking naloxone supply arrangements outside the US.
  • Supply-chain and quality teams working with Emergent may wish to ask about any operational effects of the restructuring, which the company has not detailed in the material reviewed.

Company's press release (SEC filing): Emergent BioSolutions Inc. ↗

Article written by VigiEye from the official source (Emergent BioSolutions Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →